← brief for 2026-09-28 · Slowing decline

Does higher kidney risk justify more finerenone? Reappraising absolute benefit against the safety window of FINEARTS-HF.

Article No results yet Peer reviewed

Key takeaways

This is an opinion piece about a heart failure drug called finerenone. It discusses whether people with kidney disease should take it. It argues for a careful look at the benefits and risks. There are no results yet.

Who did this work

Guo S · Li Y

Source

Article · PubMed, the drug frontier · 2026 Sep 28
https://pubmed.ncbi.nlm.nih.gov/42802359/